Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277656 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1LMNANPSR1MEN1 | |
| SCHEMBL13854477 | 0.84 | L3MBTL1 (0.70) | L3MBTL1ABCG2ALDH1A1LMNANPSR1 | |
| SCHEMBL173456 | 0.84 | L3MBTL1 (0.57) | L3MBTL1LMNANPSR1MEN1KMT2A | |
| SCHEMBL3137152 | 0.83 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1LMNANPSR1MEN1 | |
| SCHEMBL3152785 | 0.82 | L3MBTL1 (0.51) | L3MBTL1LMNANPSR1MEN1KMT2A | |
| SCHEMBL3139841 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ABCG2ALDH1A1LMNANPSR1 | |
| SCHEMBL4231756 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1LMNANPSR1MEN1 | |
| SCHEMBL2468284 | 0.81 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1LMNANPSR1MEN1 | |
| SCHEMBL2467474 | 0.81 | ALDH1A1 (0.47) | ABCG2ALDH1A1LMNANPSR1MEN1 | |
| SCHEMBL27811934 | 0.81 | L3MBTL1 (0.48) | L3MBTL1ABCG2LMNANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | L3MBTL1 3535/4885ABCG2 1736/4885ALDH1A1 277/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | L3MBTL1 3654/4885ABCG2 1846/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.